In a cross-sectional study, hyperparathyroidism occurred more frequently in adults with a diet of high vs low inflammatory potential.
Patients on hemodialysis who have secondary hyperparathyroidism experienced a 40% reduction in PTH levels over 12 months of etelcalcetide treatment, investigators reported.
In a small study, approximately a third of kidney transplant recipients had anemia and half had persistent secondary hyperparathyroidism.
Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.
Weight loss partly accounted for the association between high parathyroid hormone levels and mortality among patients on hemodialysis.
An expert panel of US nephrologists and other health care providers unanimously agreed that secondary hyperparathyroidism treatment is often started too late in patients with chronic kidney disease.
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.